Background: Reactive oxygen species (ROS) are known to be related to cardiovascular diseases. Many studies have demonstrated that angiotensin-converting enzyme inhibitors have beneficial effects against ROS. We investigated the antioxidant effect of captopril and enalapril in nitric oxide mediated vascular endothelium-dependent relaxations.

Materials And Methods: Isolated rabbit abdominal aorta ring segments were exposed to ROS by electrolysis of the organ bath medium (Krebs-Henseleit solution) after pretreatment with various concentrations (range, 10(-5) to 3×10(-4) M) of captopril and enalapril. Before and after electrolysis, the endothelial function was measured by preconstricting the vessels with norepinephrine (10(-6) M) followed by the cumulative addition of acetylcholine (range, 3×10(-8) to 10(-6) M). The relevance of the superoxide anion and hydrogen peroxide scavenging effect of captopril and enalapril was investigated using additional pretreatments of diethyldithiocarbamate (DETCA, 0.5 mM), an inhibitor of Cu/Zn superoxide dismutase, and 3-amino-1,2,4-triazole (3AT, 50 mM), an inhibitor of catalase.

Results: Both captopril and enalapril preserved vascular endothelium-dependent relaxation after exposure to ROS in a dose-dependent manner (p<0.0001). Pretreatment with DETCA attenuated the antioxidant effect of captopril and enalapril (p<0.0001), but pretreatment with 3AT did not have an effect.

Conclusion: Both captopril and enalapril protect endothelium against ROS in a dose-dependent fashion in isolated rabbit abdominal aortas. This protective effect is related to superoxide anion scavenging.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573160PMC
http://dx.doi.org/10.5090/kjtcs.2013.46.1.14DOI Listing

Publication Analysis

Top Keywords

captopril enalapril
20
antioxidant captopril
8
reactive oxygen
8
rabbit abdominal
8
abdominal aorta
8
vascular endothelium-dependent
8
enalapril
5
enalapril reactive
4
oxygen species-induced
4
species-induced endothelial
4

Similar Publications

This publication is the first to report current, global, pediatric oral extemporaneous compounding practices. Complete survey responses were received from 479 participants actively involved in compounding across all the World Health Organization (WHO) regions. The survey addressed oral formulation of extemporaneous liquids, including the use of commercial or in-house vehicles, flavoring excipients, source of formulation recipes, and beyond use dates (BUDs).

View Article and Find Full Text PDF

Boroxazolidones: Synthesis, In Silico and In Vitro Evaluation as ACE/AChE Dual Inhibitors, and In Vivo Testing of Antihypertensive Activity.

Curr Med Chem

August 2024

Unidad de Investigación en Biomedicina y Carrera de Enfermería, Facultad de Estudios Superiores-Iztacala, Universidad Nacional Autónoma de México. Av. de los Barrios 1, Los Reyes Iztacala, Tlalnepantla, 54090, Estado de México, México.

Background: Systemic arterial hypertension is a serious chronic health problem caused by multiple factors. It is a major risk factor for Cardiovascular Diseases (CVDs), including heart failure, coronary heart disease, and myocardial infarction. Hypertension can be effectively treated with inhibitors of the Angiotensin Converting Enzyme (ACE), such as captopril, enalapril, and lisinopril.

View Article and Find Full Text PDF

: This study assessed the patterns and clinical significance of potential drug-drug interactions (pDDIs) in patients with diseases of the cardiovascular system. : Electronic health records (EHRs), established in 2018-2023, were selected using the probability serial nested sampling method ( = 1030). Patients were aged 27 to 95 years (65.

View Article and Find Full Text PDF

Sensitive "release-on-demand" fluorescent genosensors for probing DNA damage induced by commonly used cardiovascular drugs: Comparative study.

Int J Biol Macromol

June 2024

Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Alexandria University, 1 El Khartoum Square, Alexandria 21521, Egypt. Electronic address:

Cardiovascular drugs (CVDs) are agents working on the heart and the vascular system to treat many cardiovascular disorders. Such disorders represent the leading cause for morbidity and mortality worldwide. The treatment regimen includes different administered drugs on chronic basis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!